Loki Home

Research Interests

Funding Opportunities

FAQ

UI Login Guest Login

Browse by Investigator Last Name



Browse Research


Photo of Koen De Geest

Koen De Geest

This person no longer has an active appointment with the University of Iowa.

Education

BS, Basic Sciences, University of Gent, Belgium
MD, Medicine, University of Gent, Belgium
Internship, Obstetrics and Gynecology, University of Gent, Belgium
Residency, Obstetrics and Gynecology, University of Gent, Belgium
Fellowship, Gynecologic Oncology, Hershey Medical Center, Pennsylvania State University

Research Interests


MeSH Terms from Publications

Ovarian Neoplasms, Female, Peritoneal Neoplasms, Humans, Middle Aged, Aged, Neoplasm Recurrence, Local, Adult, Neoplasm Staging, Aged, 80 and over, Endometrial Neoplasms, Paclitaxel, Uterine Cervical Neoplasms, Taxoids, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cervix Uteri, Neoplasms, Glandular and Epithelial, Vulvar Neoplasms, Uterine Neoplasms, Combined Modality Therapy, Proportional Hazards Models, Cisplatin, Topotecan, Papillomaviridae

Research Summary



Recent Publications


Show publications
  1. Stone, R, Nick, A, McNeish, I, Balkwill, F, Han, H, Bottsford-Miller, J, Rupairmoole, R, Armaiz-Pena, G, Pecot, C, Coward, J, Deavers, M, Vasquez, H, Urbauer, D, Landen, C, Hu, W, Gershenson, H, Matsuo, K, Shahzad, M, King, E, Tekedereli, I, Ozpolat, B, Ahn, E, Bond, V, Wang, R, Drew, A, Gushiken, F, Lamkin, D, Collins, K, DeGeest, K, Lutgendorf, S, Chiu, W, Lopez-Berestein, G, Afshar-Kharghan, V, Sood, A. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2012. [PubMed]
  2. Herzog, T, Sill, M, Walker, J, O'Malley, D, Shahin, M, DeGeest, K, Weiner, S, Mutch, D, DeBernardo, R, Lentz, S. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 120(3):454-8, 2011. [PubMed]
  3. Matei, D, Sill, M, Lankes, H, DeGeest, K, Bristow, R, Mutch, D, Yamada, S, Cohn, D, Calvert, V, Farley, J, Petricoin, E, Birrer, M. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29(1):69-75, 2011. [PubMed]
  4. Lutgendorf, S, DeGeest, K, Dahmoush, L, Farley, D, Penedo, F, Bender, D, Goodheart, M, Buekers, T, Mendez, L, Krueger, G, Clevenger, L, Lubaroff, D, Sood, A, Cole, S. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25(2):250-5, 2011. [PubMed]
  5. Nadkarni, N, Rogers, L, Samuelson, M, Neff, T, Bender, D, Ahmed, A, De Geest, K, Button, A, Dupuy, A, Goodheart, M. Zmiz1 is overexpressed in epithelial ovarian cancer and associated with p53 gene mutations. GYNECOLOGIC ONCOLOGY 123(2):446-447, NOV 2011.
  6. Girardi, JR, Samuelson, M, Button, A, De Geest, K, Bender, D, Ahmed, A, Goodheart, MJ. The relationship between vascularity, p53 gene mutations and distant metastatic disease in epithelial ovarian carcinoma. GYNECOLOGIC ONCOLOGY 123(2):443-443, NOV 2011.
  7. Clements, A, Engle, D, Shelton, D, Neff, T, Park, S, Bender, D, Ahmed, A, De Geest, K, Button, A, Engelhardt, J, Goodheart, M. Lymphoid enhancing factor 1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancers and associations with clinical factors. GYNECOLOGIC ONCOLOGY 123(2):437-437, NOV 2011.
  8. Usha, L, Sill, M, Darcy, K, Benbrook, D, Hurteau, J, Michelin, D, Mannel, R, Hanjani, P, De Geest, K, Godwin, A. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 121(3):455-61, 2011. [PubMed]
  9. Monk, B, Sill, M, Hanjani, P, Edwards, R, Rotmensch, J, De Geest, K, Bonebrake, A, Walker, J. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 120(3):459-63, 2011. [PubMed]
  10. Nadkarni, N, Rogers, L, Samuelson, M, Neff, T, Bender, D, Ahmed, A, De Geest, K, Button, A, Dupuy, A, Goodheart, M. Zmiz1 is overexpressed in epithelial ovarian cancer and associated with p53 gene mutations. GYNECOLOGIC ONCOLOGY 123(2):446-447, NOV 2011.